Cytomegalovirus immune globulin - Biotest

Drug Profile

Cytomegalovirus immune globulin - Biotest

Alternative Names: BT-084; BT-094; CMV-Gyn; Cytotect; Cytotect 70; Cytotect CP; Cytotect FH; HCMV-specific hyperimmune globulin - Biotest; Human cytomegalovirus immunoglobulin; Human normal immunoglobulin; Megalotect; Neocytotect

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotest
  • Developer Biotest AG
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cytomegalovirus infections

Most Recent Events

  • 27 Sep 2017 Biotest's cytomegalovirus immune globulin is still at phase III development stage for Cytomegalovirus infections (Prevention) in Austria, Belgium, Germany, Hungary and Italy (IV) (Biotest pipeline, September 2017)
  • 22 Dec 2016 Biotest completes a phase III trial for Cytomegalovirus infections (Prevention) in Austria, Belgium, Germany, Hungary and Italy (EudraCT2007-004692-19)
  • 03 Sep 2015 Biotest completes enrolment in its phase III trial for Cytomegalovirus infections (Prevention) in Austria, Belgium, Germany, Hungary and Italy (EudraCT2007-004692-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top